Cargando…

Positron Emission Tomography Combined With Computed Tomography as a Screening Tool for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism: An Observational Study

Venous thromboembolism (VTE) can be the first clinical manifestation of an occult malignancy. We aimed to assess the value, in daily practice, of positron emission tomography combined with computed tomography (PET-CT) for occult malignancy diagnosis in patients with unprovoked VTE. All PET-CTs perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chauchard, Maria, Benali, Khadija, Papo, Thomas, Sacre, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616277/
https://www.ncbi.nlm.nih.gov/pubmed/25380083
http://dx.doi.org/10.1097/MD.0000000000000110
_version_ 1782396596315488256
author Chauchard, Maria
Benali, Khadija
Papo, Thomas
Sacre, Karim
author_facet Chauchard, Maria
Benali, Khadija
Papo, Thomas
Sacre, Karim
author_sort Chauchard, Maria
collection PubMed
description Venous thromboembolism (VTE) can be the first clinical manifestation of an occult malignancy. We aimed to assess the value, in daily practice, of positron emission tomography combined with computed tomography (PET-CT) for occult malignancy diagnosis in patients with unprovoked VTE. All PET-CTs performed over 5-years period (from January 2009 to October 2013) in adult patients followed in the Department of Internal Medicine (Bichat Hospital, Paris, France) were retrospectively reviewed. Clinical history, imaging findings, and additional diagnostic tests performed because of PET-CT findings were analyzed. From January 2009 to October 2013, PET-CT was performed for malignancy diagnosis in 67 consecutive patients with unprovoked VTE. Seventeen patients were excluded because of congenital or acquired thrombophilia, known cancer, estrogen use, inability to confirm VTE diagnosis, or missing data. Fifty patients (25 women; mean age, 65.2 ± 15.9 years) were included. VTE was a first episode in 84% of cases. In 22 (44%) patients, PET-CT showed increased uptake suspicious for malignancy. After additional procedures, malignancy was confirmed in 12/22 patients. In all cases of confirmed malignancies, conventional computed tomography scan (CT-scan) had similar diagnosis yield, as compared with PET-CT. In 10/22 cases, the suspected diagnosis of malignancy could not be confirmed despite extensive workup including specialist visits (n = 5), magnetic resonance imaging (n = 4), gastrointestinal tract endoscopy (n = 3), endometrial biopsies (n = 2), and hysterectomy (n = 1). The cost of additional diagnosis procedures performed because of false positive PET-CT amounted to є1956/patient. Interestingly, considering CT-scan findings only, no further investigation would have been scheduled. No patient with negative or false positive PET-CT was diagnosed with cancer during a mean follow-up of 22 ± 13.6 months. A diagnosis strategy based on PET-CT screening for malignancy in patients with unprovoked VTE had limited diagnosis value and may lead to unnecessary alarming and money- and time-consuming investigations.
format Online
Article
Text
id pubmed-4616277
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46162772015-10-27 Positron Emission Tomography Combined With Computed Tomography as a Screening Tool for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism: An Observational Study Chauchard, Maria Benali, Khadija Papo, Thomas Sacre, Karim Medicine (Baltimore) 5700 Venous thromboembolism (VTE) can be the first clinical manifestation of an occult malignancy. We aimed to assess the value, in daily practice, of positron emission tomography combined with computed tomography (PET-CT) for occult malignancy diagnosis in patients with unprovoked VTE. All PET-CTs performed over 5-years period (from January 2009 to October 2013) in adult patients followed in the Department of Internal Medicine (Bichat Hospital, Paris, France) were retrospectively reviewed. Clinical history, imaging findings, and additional diagnostic tests performed because of PET-CT findings were analyzed. From January 2009 to October 2013, PET-CT was performed for malignancy diagnosis in 67 consecutive patients with unprovoked VTE. Seventeen patients were excluded because of congenital or acquired thrombophilia, known cancer, estrogen use, inability to confirm VTE diagnosis, or missing data. Fifty patients (25 women; mean age, 65.2 ± 15.9 years) were included. VTE was a first episode in 84% of cases. In 22 (44%) patients, PET-CT showed increased uptake suspicious for malignancy. After additional procedures, malignancy was confirmed in 12/22 patients. In all cases of confirmed malignancies, conventional computed tomography scan (CT-scan) had similar diagnosis yield, as compared with PET-CT. In 10/22 cases, the suspected diagnosis of malignancy could not be confirmed despite extensive workup including specialist visits (n = 5), magnetic resonance imaging (n = 4), gastrointestinal tract endoscopy (n = 3), endometrial biopsies (n = 2), and hysterectomy (n = 1). The cost of additional diagnosis procedures performed because of false positive PET-CT amounted to є1956/patient. Interestingly, considering CT-scan findings only, no further investigation would have been scheduled. No patient with negative or false positive PET-CT was diagnosed with cancer during a mean follow-up of 22 ± 13.6 months. A diagnosis strategy based on PET-CT screening for malignancy in patients with unprovoked VTE had limited diagnosis value and may lead to unnecessary alarming and money- and time-consuming investigations. Wolters Kluwer Health 2014-10-31 /pmc/articles/PMC4616277/ /pubmed/25380083 http://dx.doi.org/10.1097/MD.0000000000000110 Text en © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Chauchard, Maria
Benali, Khadija
Papo, Thomas
Sacre, Karim
Positron Emission Tomography Combined With Computed Tomography as a Screening Tool for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism: An Observational Study
title Positron Emission Tomography Combined With Computed Tomography as a Screening Tool for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism: An Observational Study
title_full Positron Emission Tomography Combined With Computed Tomography as a Screening Tool for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism: An Observational Study
title_fullStr Positron Emission Tomography Combined With Computed Tomography as a Screening Tool for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism: An Observational Study
title_full_unstemmed Positron Emission Tomography Combined With Computed Tomography as a Screening Tool for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism: An Observational Study
title_short Positron Emission Tomography Combined With Computed Tomography as a Screening Tool for Occult Malignancy in Patients With Unprovoked Venous Thromboembolism: An Observational Study
title_sort positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616277/
https://www.ncbi.nlm.nih.gov/pubmed/25380083
http://dx.doi.org/10.1097/MD.0000000000000110
work_keys_str_mv AT chauchardmaria positronemissiontomographycombinedwithcomputedtomographyasascreeningtoolforoccultmalignancyinpatientswithunprovokedvenousthromboembolismanobservationalstudy
AT benalikhadija positronemissiontomographycombinedwithcomputedtomographyasascreeningtoolforoccultmalignancyinpatientswithunprovokedvenousthromboembolismanobservationalstudy
AT papothomas positronemissiontomographycombinedwithcomputedtomographyasascreeningtoolforoccultmalignancyinpatientswithunprovokedvenousthromboembolismanobservationalstudy
AT sacrekarim positronemissiontomographycombinedwithcomputedtomographyasascreeningtoolforoccultmalignancyinpatientswithunprovokedvenousthromboembolismanobservationalstudy